ESC Premium Access

Tolvaptan reduces the risk of worsening renal function in patients admitted for acute decompensated heart failure with preserved left ventricular ejection fraction: a prospective randomized controlled

Congress Presentation

About the speaker

Doctor Yoshihiro Sato

Fujita Health University, Toyoake (Japan)
0 follower

49 more presentations in this session

Survival in HFpEF vs HFrEF patients after beta-blocker titration: new insights from the CIBIS-ELD trial

Speaker: Professor H. Duengen (Berlin, DE)

Thumbnail

Dual V1a/V2 versus selective V2 vasopressin receptor blockade in a preclinical heart failure model: does it matter?

Speaker: Doctor T. Mondritzki (Wuppertal, DE)

Thumbnail

The use of Guideline recommended betablocker therapy in primary prevention ICD patients. Insight from Danish nationwide registries

Speaker: Doctor A. Huth Ruwald (Copenhagen, DK)

Thumbnail

The effect of angiotensin II type 2 receptor agonist treatment on doxorubicin induced heart failure

Speaker: Associate Professor N. Ermis (Malatya, TR)

Thumbnail

Triiodo-L-thyronine promotes the therapeutic efficacy for myocardial infarction of bone marrow mesenchymal stem cells

Speaker: Professor S. Nie (Beijing, CN)

Thumbnail

Access the full session

Poster session 7 - Heart failure / Left ventricular dysfunction

Speakers: Doctor Y. Sato, Professor H. Duengen, Doctor T. Mondritzki, Doctor A. Huth Ruwald, Associate Professor N. Ermis...
Thumbnail

About the event

Image

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations